trending Market Intelligence /marketintelligence/en/news-insights/trending/xQbkNvCY1NtJEJ9DgxCmmA2 content esgSubNav
In This List

Mesoblast gets $40M from Tasly Pharmaceutical in heart drug duo deal

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Mesoblast gets $40M from Tasly Pharmaceutical in heart drug duo deal

Melbourne, Australia-based Mesoblast Ltd. received $40 million from Tasly Pharmaceutical Group Co. Ltd. after completing a collaboration in China for a pair of Mesoblast heart drug candidates.

As part of the strategic partnership, Tasly has received exclusive rights in China for MPC-150-IM for preventing and treating chronic heart failure and MPC-25-IC for preventing and treating heart attack. The Tianjin, China-based drug distributor will fund all development, manufacturing and commercialization of both medicines in the country.

The payment comprises a $20 million up-front technology access fee and a $20 million equity purchase for which Mesoblast has issued 14,464,259 fully paid ordinary shares to Tasly.

Mesoblast would receive $25 million upon receiving certain regulatory approvals for the products in China. The cellular drug developer could also get double-digit escalating royalties on net product sales, as well as six additional escalating milestone payments upon the achievement of certain sales thresholds.

Mesoblast and Tasly will set up a joint steering committee, with equal representation, to accelerate developing and commercializing the heart therapies in China.